COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial

This publication has 49 references indexed in Scilit:

• Activation of the Thromboxane A2 Pathway in Human Prostate Cancer Correlates with Tumor Gleason Score and Pathologic Stage
  European Urology, 2006
• Cyclooxygenase‐2 (cox‐2) expression is an independent predictor of prostate cancer recurrence
  International Journal of Cancer, 2006
• Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy
  Clinical Cancer Research, 2006
• High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer
  Clinical Cancer Research, 2005
• Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens
  European Urology, 2005
• Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease
  Prostate Cancer and Prostatic Diseases, 2005
• Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade
  Prostate Cancer and Prostatic Diseases, 2005
• Inhibition of Cyclooxygenase (COX)-2 Expression by Tet-Inducible COX-2 Antisense cDNA in Hormone-Refractory Prostate Cancer Significantly Slows Tumor Growth and Improves Efficacy of Chemotherapeutic Drugs
  Clinical Cancer Research, 2004
• Cyclooxygenase-2 Inhibitor NS398 Enhances Antitumor Effect of Irradiation on Hormone Refractory Human Prostate Carcinoma Cells
  Journal of Urology, 2003
• CYCLOOXYGENASES 1 AND 2
  Annual Review of Pharmacology and Toxicology, 1998